Abstract
BackgroundTofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).ObjectivesThis analysis provides comparative safety data on the incidence of safety events for patients (pts) with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have